An official website of the United States government
Home
SEER Inquiry System - Report
Produced: 10/14/2025 9:23 AM
Question 20240071
Inquiry Details
References:
#1: Heme & Lymph Manual & DB. Published August 2021
#2: Journal article. https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00555-2/fulltext
Question:
Heme and Lymphoid Neoplasms/Multiple Primaries--Myeloproliferative Neoplasms: Are essential thrombocytosis (ET) in 1998 and primary myelofibrosis in 2022 the same primary or is the 2022 diagnosis a new primary? See Discussion.
Discussion:
Patient was diagnosed with essential thrombocytosis 9962/1 or 3 in 1998 (depending if ET was reportable in 1998), treated with Hydrea.
11-17-2022 Blood smear: CALR + myeloproliferative neoplasm, Most Consistent with Primary Myelofibrosis 9961/3 (Noted CALR and ASXL1 mutations).
The following abstractor note from 9661/3 is confusing: A diagnosis of "post essential thrombocythemia myelofibrosis" is a progression of essential thrombocythemia and would be the same primary.
Answer:
Answer updated September 2025:
Abstract a single primary as primary myelofibrosis (9961/3). ET was not reportable in 1998.
